Paul Tudor Jones Pacira Bio Sciences, Inc. Transaction History
Tudor Investment Corp Et Al
- $25.1 Billion
- Q4 2024
A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 22,649 shares of PCRX stock, worth $569,848. This represents 0.0% of its overall portfolio holdings.
Number of Shares
22,649Holding current value
$569,848% of portfolio
0.0%Shares
20 transactions
Others Institutions Holding PCRX
# of Institutions
260Shares Held
49.8MCall Options Held
1.03MPut Options Held
139K-
Black Rock Inc. New York, NY8.01MShares$201 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.26MShares$132 Million0.0% of portfolio
-
Pacer Advisors, Inc. Malvern, PA3.26MShares$82.1 Million0.15% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY2.26MShares$56.8 Million0.03% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.99MShares$50.1 Million0.06% of portfolio
About Pacira BioSciences, Inc.
- Ticker PCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 45,824,200
- Market Cap $1.15B
- Description
- Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...